



NOT FOR DISTRIBUTION IN THE UNITED STATES

Telescope Provides Update on Private Placement

Vancouver, BC — March 21, 2025 — Telescope Innovations Corp. (“**Telescope**” or the “**Company**”) (CSE: TELI), a chemical technology company, announces that it is continuing to pursue the previously announced non-brokered private placement (the “**Offering**”) under the Listed Issuer Financing Exemption (as defined below). The Company is offering units (each, a “**Unit**”) at a price of \$0.40 to raise gross proceeds of up to \$3,000,000. Each Unit consists of one common share of the Company and one common share purchase warrant (each, a “**Warrant**”). Each Warrant entitles the holder to purchase an additional common share at a price of \$0.75 for a period of thirty-six months, subject to accelerated expiry upon the closing price of the Company’s common shares on the Canadian Securities Exchange exceeding \$1.25 or more for the preceding sixty consecutive trading days.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (“**NI 45-106**”), the Offering is being made to purchasers’ resident in Canada, except Quebec, as well as certain jurisdictions outside of Canada, pursuant to the listed issuer financing exemption under Part 5A of NI- 45-106 (the “**Listed Issuer Financing Exemption**”).

For more information regarding the Offering, readers are encouraged to review the Company’s news release issued on February 4, 2025 and the amended and restated offering document filed by the Company, a copy of which is accessible under the Company’s profile on SEDAR+ (www.sedarplus.ca) and on the corporate website (www.telescopeinnovations.com).

About Telescope Innovations

Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. The Company’s aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.

On behalf of the Board,

Telescope Innovations Corp.

Henry Dubina, CEO

For additional information, please contact

Jeffrey Sherman, COO

E: jeff@telescopeinn.com

Forward-Looking Information

The Canadian Securities Exchange (“**CSE**”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “forward-looking information” under applicable Canadian securities laws. When or if used in this news release, the words “anticipate,” “believe,” “estimate,” “expect,” “target”, “plan,” “forecast,” “may,” “schedule,” and similar words or expressions identify forward-looking information. This forward-looking information may relate to planned project development, exploration programs, the intended use of the proceeds from the Offering and other factors or information.

Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. The forward-looking information contained in this news release is made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.